| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 25 | 2025 | 1705 | 3.810 |
Why?
|
| Glioblastoma | 13 | 2023 | 331 | 3.590 |
Why?
|
| Immunotherapy, Adoptive | 16 | 2025 | 871 | 2.800 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2020 | 458 | 2.310 |
Why?
|
| Brain Neoplasms | 13 | 2023 | 1224 | 2.190 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 5 | 2018 | 20 | 1.840 |
Why?
|
| Immunotherapy | 11 | 2017 | 740 | 1.830 |
Why?
|
| Sarcoma | 3 | 2025 | 205 | 1.290 |
Why?
|
| Adoptive Transfer | 6 | 2015 | 228 | 1.270 |
Why?
|
| Immunological Synapses | 2 | 2025 | 32 | 1.010 |
Why?
|
| Medulloblastoma | 5 | 2020 | 378 | 0.960 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 60 | 0.870 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 114 | 0.850 |
Why?
|
| Antigens, Neoplasm | 4 | 2020 | 398 | 0.820 |
Why?
|
| Neoplasms | 6 | 2025 | 2852 | 0.780 |
Why?
|
| Tumor Microenvironment | 4 | 2016 | 628 | 0.700 |
Why?
|
| Antigenic Variation | 2 | 2018 | 37 | 0.700 |
Why?
|
| Tumor Escape | 3 | 2016 | 62 | 0.660 |
Why?
|
| Liver Diseases | 2 | 2019 | 381 | 0.660 |
Why?
|
| Receptor, EphA2 | 2 | 2018 | 28 | 0.660 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 22 | 0.660 |
Why?
|
| Flow Cytometry | 6 | 2017 | 754 | 0.640 |
Why?
|
| Cancer Vaccines | 3 | 2020 | 188 | 0.620 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 45 | 0.610 |
Why?
|
| Cerebellar Neoplasms | 3 | 2020 | 314 | 0.600 |
Why?
|
| Mice, SCID | 9 | 2023 | 568 | 0.590 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 208 | 0.530 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 336 | 0.530 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 143 | 0.520 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2017 | 512 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2023 | 1168 | 0.510 |
Why?
|
| Vidarabine | 2 | 2024 | 83 | 0.500 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 304 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1234 | 0.490 |
Why?
|
| Hematologic Neoplasms | 4 | 2025 | 294 | 0.480 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2025 | 946 | 0.480 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 3497 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 988 | 0.470 |
Why?
|
| Viral Matrix Proteins | 2 | 2015 | 107 | 0.470 |
Why?
|
| Microspheres | 1 | 2015 | 68 | 0.470 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 57 | 0.460 |
Why?
|
| Humans | 54 | 2025 | 126679 | 0.460 |
Why?
|
| Immunophenotyping | 1 | 2015 | 330 | 0.440 |
Why?
|
| Phosphoproteins | 1 | 2015 | 420 | 0.400 |
Why?
|
| Lymphoma | 2 | 2024 | 319 | 0.370 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 191 | 0.360 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1569 | 0.360 |
Why?
|
| Mice | 20 | 2025 | 17594 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 331 | 0.350 |
Why?
|
| Chemotaxis | 1 | 2011 | 59 | 0.350 |
Why?
|
| Osteosarcoma | 2 | 2015 | 259 | 0.340 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 678 | 0.340 |
Why?
|
| Animals | 24 | 2025 | 33045 | 0.330 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 428 | 0.330 |
Why?
|
| Antigens, Viral | 1 | 2012 | 389 | 0.320 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 55 | 0.320 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 257 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 985 | 0.300 |
Why?
|
| CD28 Antigens | 2 | 2025 | 74 | 0.300 |
Why?
|
| Yellow Fever Vaccine | 1 | 2009 | 42 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 56 | 0.290 |
Why?
|
| Yellow Fever | 1 | 2009 | 78 | 0.290 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2025 | 258 | 0.280 |
Why?
|
| Male | 21 | 2025 | 62490 | 0.270 |
Why?
|
| Endothelial Cells | 1 | 2011 | 501 | 0.270 |
Why?
|
| beta-Thalassemia | 1 | 2007 | 26 | 0.270 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 120 | 0.260 |
Why?
|
| Treatment Outcome | 7 | 2024 | 12537 | 0.260 |
Why?
|
| Child | 15 | 2025 | 25081 | 0.260 |
Why?
|
| Oncogenic Viruses | 1 | 2006 | 17 | 0.250 |
Why?
|
| Cell Proliferation | 5 | 2018 | 2397 | 0.250 |
Why?
|
| Cell Transformation, Viral | 1 | 2006 | 95 | 0.250 |
Why?
|
| Signal Transduction | 2 | 2025 | 4472 | 0.240 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 1758 | 0.240 |
Why?
|
| Endoglin | 1 | 2025 | 31 | 0.240 |
Why?
|
| Genome, Viral | 1 | 2006 | 153 | 0.240 |
Why?
|
| Tumor Virus Infections | 1 | 2006 | 130 | 0.230 |
Why?
|
| Pneumococcal Infections | 1 | 2007 | 276 | 0.230 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 421 | 0.230 |
Why?
|
| Streptococcus pneumoniae | 1 | 2007 | 377 | 0.220 |
Why?
|
| Vaccines | 1 | 2010 | 381 | 0.220 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 26 | 0.220 |
Why?
|
| Lymphocyte Activation | 4 | 2025 | 669 | 0.220 |
Why?
|
| Graft Rejection | 1 | 2008 | 553 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 439 | 0.210 |
Why?
|
| Alemtuzumab | 2 | 2018 | 87 | 0.210 |
Why?
|
| Adult | 9 | 2024 | 30379 | 0.210 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 325 | 0.200 |
Why?
|
| Mice, Inbred NOD | 3 | 2023 | 289 | 0.200 |
Why?
|
| Female | 16 | 2025 | 68275 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 53 | 0.190 |
Why?
|
| Child, Preschool | 11 | 2025 | 14336 | 0.190 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 75 | 0.190 |
Why?
|
| Adolescent | 10 | 2025 | 19987 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 89 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 152 | 0.190 |
Why?
|
| Leukemia | 1 | 2024 | 356 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 314 | 0.170 |
Why?
|
| Antigens, CD19 | 2 | 2020 | 171 | 0.170 |
Why?
|
| Glioma | 2 | 2017 | 479 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 62 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 23 | 0.160 |
Why?
|
| Middle Aged | 5 | 2024 | 27672 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2024 | 6203 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 95 | 0.160 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 265 | 0.160 |
Why?
|
| Freezing | 1 | 2019 | 24 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2021 | 194 | 0.160 |
Why?
|
| Remission Induction | 1 | 2020 | 298 | 0.160 |
Why?
|
| Biopsy | 2 | 2020 | 1236 | 0.150 |
Why?
|
| Transduction, Genetic | 4 | 2020 | 283 | 0.150 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2022 | 213 | 0.150 |
Why?
|
| Transgenes | 2 | 2020 | 330 | 0.150 |
Why?
|
| Protein Stability | 1 | 2019 | 162 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5113 | 0.150 |
Why?
|
| Ependymoma | 1 | 2020 | 139 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2020 | 309 | 0.140 |
Why?
|
| Infant | 7 | 2025 | 12760 | 0.140 |
Why?
|
| Osteopontin | 1 | 2018 | 51 | 0.140 |
Why?
|
| Aged | 4 | 2024 | 20321 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Neoplasms, Experimental | 2 | 2010 | 203 | 0.140 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 70 | 0.140 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2008 | 104 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2017 | 60 | 0.130 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 686 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 2 | 2017 | 613 | 0.130 |
Why?
|
| Protein Binding | 2 | 2020 | 1661 | 0.120 |
Why?
|
| Adenoviridae | 2 | 2017 | 573 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 204 | 0.120 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 639 | 0.120 |
Why?
|
| Interleukin-13 | 1 | 2016 | 94 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2020 | 767 | 0.120 |
Why?
|
| Polystyrenes | 1 | 2015 | 8 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 361 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2016 | 138 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 422 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 269 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 159 | 0.120 |
Why?
|
| Survival Rate | 4 | 2017 | 2100 | 0.120 |
Why?
|
| Color | 1 | 2015 | 32 | 0.120 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 12 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 222 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 272 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 174 | 0.110 |
Why?
|
| In Situ Hybridization | 2 | 2013 | 449 | 0.110 |
Why?
|
| Apoptosis | 2 | 2018 | 1811 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 267 | 0.110 |
Why?
|
| Recurrence | 2 | 2015 | 1406 | 0.110 |
Why?
|
| Separase | 1 | 2014 | 28 | 0.110 |
Why?
|
| Leukocytes | 1 | 2015 | 202 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 245 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 351 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 973 | 0.110 |
Why?
|
| Astrocytes | 1 | 2017 | 260 | 0.110 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 111 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2010 | 2893 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 652 | 0.100 |
Why?
|
| Antigens, CD1d | 1 | 2013 | 20 | 0.100 |
Why?
|
| NFI Transcription Factors | 1 | 2013 | 50 | 0.100 |
Why?
|
| Synapses | 1 | 2017 | 433 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 783 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 291 | 0.100 |
Why?
|
| Retroviridae | 2 | 2012 | 182 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1048 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2036 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 898 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 94 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2014 | 551 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1559 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2024 | 199 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 824 | 0.090 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 33 | 0.090 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 219 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 52 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 786 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2025 | 16985 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 774 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 968 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 130 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 606 | 0.080 |
Why?
|
| Biological Assay | 1 | 2010 | 106 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1221 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 217 | 0.080 |
Why?
|
| Mice, Inbred ICR | 1 | 2010 | 152 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2010 | 229 | 0.070 |
Why?
|
| Young Adult | 3 | 2024 | 9655 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1351 | 0.070 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 45 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 269 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 1 | 2008 | 57 | 0.070 |
Why?
|
| Models, Biological | 1 | 2013 | 1370 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1597 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2009 | 186 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2009 | 154 | 0.070 |
Why?
|
| Cytokines | 2 | 2020 | 1317 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2012 | 683 | 0.070 |
Why?
|
| Living Donors | 1 | 2008 | 115 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1493 | 0.070 |
Why?
|
| Brain | 3 | 2018 | 3037 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2039 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 132 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 358 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 872 | 0.060 |
Why?
|
| Gene Expression | 2 | 2022 | 1482 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 394 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 133 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2015 | 4953 | 0.060 |
Why?
|
| Prognosis | 3 | 2025 | 4772 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 189 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 330 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1198 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1135 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 541 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 302 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 133 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 125 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2017 | 230 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 630 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3693 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 46 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 2310 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 198 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2537 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 222 | 0.050 |
Why?
|
| Egypt | 1 | 2022 | 27 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 136 | 0.050 |
Why?
|
| Ghrelin | 1 | 2022 | 57 | 0.050 |
Why?
|
| TRPV Cation Channels | 1 | 2022 | 45 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 4426 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2006 | 757 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 55 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3219 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 204 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 565 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 30 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2018 | 72 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2017 | 25 | 0.030 |
Why?
|
| Antigens | 1 | 2017 | 145 | 0.030 |
Why?
|
| Biotechnology | 1 | 2017 | 56 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 41 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 189 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 264 | 0.030 |
Why?
|
| Microscopy | 1 | 2017 | 121 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 302 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 1931 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2593 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 269 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2018 | 8343 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 333 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2014 | 6 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 517 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 113 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 135 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 228 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 398 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 95 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1859 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 234 | 0.020 |
Why?
|
| Seizures | 1 | 2017 | 847 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 585 | 0.020 |
Why?
|
| Neuroglia | 1 | 2013 | 208 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 115 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1222 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3311 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 125 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3247 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 519 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1051 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 890 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 273 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 986 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 841 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 3387 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 11 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 1919 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 53 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2007 | 156 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2007 | 131 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2007 | 415 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 416 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 435 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10545 | 0.010 |
Why?
|